“We recognize the immense challenges researchers face in rare disease studies,” said the senior scientific officer of Protheragen. “Our diagnostic development services offer tailored solutions designed to accelerate the pace of discovery in rare disease research. By providing innovative diagnostic tools and support, we empower researchers to take significant steps toward effective treatments.”
Protheragen’s rare disease diagnostic development services cover in vitro diagnostic (IVD) product development, point-of-care test (POCT) development, , and companion diagnostic development. By leveraging its expertise in assay development, biomarker identification, and regulatory compliance, Protheragen aims to advance rare disease diagnostics and accelerate the path from diagnostic research to commercialization.
With years of experience and top-tier lab facilities, Protheragen has established collaboration with academic institutions and industry partners and is always committed to driving innovation and translating scientific discoveries into practical applications that can significantly contribute to the investigation of rare diseases.Statistics: Posted by babarasmith — Thu Dec 26, 2024 7:05 am
]]>